M G Robson
Affiliation: King's College London
- Toll-like receptor 2 or toll-like receptor 4 deficiency does not modify lupus in MRLlpr miceSimon J Freeley
MRC Centre for Transplantation King s College London, London, United Kingdom
PLoS ONE 8:e74112. 2013..These results show that Toll-like receptor 2 and Toll-like receptor 4 do not play a significant role in MRLlpr mice, and therefore they may not be important in human lupus. ..
- Antibody-mediated glomerulonephritis in mice: the role of endotoxin, complement and genetic backgroundM G Robson
Division of Medicine and Department Histopathology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
Clin Exp Immunol 133:326-33. 2003..C1q may play a protective role in mixed-strain 129/Sv x C57BL/6 mice, but the data may also be explained by systematic bias in background genes, as there is a large difference in disease susceptibility between C57BL/6 and 129/Sv mice...
- Toll-like receptors and renal diseaseMichael G Robson
Medical Research Council Centre for Transplantation, Kings College London School of Medicine, Guy s Hospital, London SE1 9RT, UK
Nephron Exp Nephrol 113:e1-7. 2009..I also discuss evidence that they are important in other forms of glomerulonephritis, with evidence derived mainly from experimental models in which exogenous ligands have been administered...
- Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient miceM G Robson
Division of Medicine, Imperial College School of Science, Technology, and Medicine, Hammersmith Hospital, Du Cane Road, London W12 0NN, United Kingdom
J Immunol 166:6820-8. 2001..The increased IgG deposits and apoptotic cells in the glomeruli of C1q-deficient mice suggest that the exacerbation of disease may be due to a defect in the clearance of immune complexes and/or apoptotic cells from their kidneys...
- Animal models of anti-neutrophil cytoplasmic antibody-associated vasculitisA M Coughlan
King s College London, King s Health Partners, Medical Research Council MRC Centre for Transplantation, Guy s Hospital, London SE1 9RT, UK
Clin Exp Immunol 169:229-37. 2012..Other potential therapies studied in these models include the use of bortezemib and strategies to modify antibody glycosylation...